Radiotherapeutic OK'd for Neuroendocrine Tumors.
The FDA has approved the first drug for locally advanced or metastatic pheochromocytoma and paraganglioma-a radioactive isotope of iodine called iobenguane I 131 that's absorbed by tumor cells. Twenty-five percent of patients who received it reduced their use of antihypertensive drugs by half for at least 6 months.